Pasternak R D, Hubbs S J, Caccese R G, Marks R L, Conaty J M, DiPasquale G
Clin Immunol Immunopathol. 1986 Dec;41(3):351-67. doi: 10.1016/0090-1229(86)90006-1.
Supernatants from the P388D1 murine macrophage cell line as well as commercially prepared human interleukin-1 (IL-1) stimulated primary rabbit articular chondrocytes to produce collagen- and proteoglycan-degrading proteases. The P388D1-derived factor had a molecular weight of 16,000-20,000 and a pI of 4.5-5.0, and was sensitive to phenylglyoxal treatment. Human IL-1 and the P388D1 supernatants enhanced glycosaminoglycan (GAG) release from bovine nasal cartilage explants. The proteoglycan- and collagen-degrading proteases required Ca2+ for activity. Latent proteoglycanase and collagenase had molecular weights of 44,000-56,500 and 34,000-44,000, respectively. The activated proteases had molecular weights of 30,000-40,000 and 22,000-36,000, respectively. Heparin-Sepharose affinity chromatography yielded two latent proteoglycanase-degrading protease activities and a collagen-degrading peak. The two proteoglycanase peaks also degraded fibronectin, laminin, gelatin, and azocoll but not type I collagen. The collagenase peak also degraded proteoglycan, gelatin, fibronectin, laminin, and azocoll. The activity of the proteoglycan- and collagen-degrading peaks was inhibited by phenanthroline and alpha 2-macroglobulin but not by phenylmethylsulfonylfluoride (PMSF), tosyllysylchloromethylketone (TLCK), pepstatin, or alpha 1-antitrypsin. The control of factors which augment protease production may offer a novel therapeutic approach to arthritis.
来自P388D1小鼠巨噬细胞系的上清液以及市售的人白细胞介素-1(IL-1)可刺激原代兔关节软骨细胞产生降解胶原蛋白和蛋白聚糖的蛋白酶。源自P388D1的因子分子量为16,000 - 20,000,等电点为4.5 - 5.0,并且对苯乙二醛处理敏感。人IL-1和P388D1上清液可增强牛鼻软骨外植体中糖胺聚糖(GAG)的释放。降解蛋白聚糖和胶原蛋白的蛋白酶的活性需要Ca2+。潜在的蛋白聚糖酶和胶原酶的分子量分别为44,000 - 56,500和34,000 - 44,000。活化后的蛋白酶分子量分别为30,000 - 40,000和22,000 - 36,000。肝素-琼脂糖亲和层析产生了两种潜在的降解蛋白聚糖酶的蛋白酶活性和一个降解胶原蛋白的峰。这两个蛋白聚糖酶峰也可降解纤连蛋白、层粘连蛋白、明胶和偶氮胶原蛋白,但不降解I型胶原蛋白。胶原酶峰也可降解蛋白聚糖、明胶、纤连蛋白、层粘连蛋白和偶氮胶原蛋白。降解蛋白聚糖和胶原蛋白峰的活性受到菲咯啉和α2-巨球蛋白的抑制,但不受苯甲基磺酰氟(PMSF)、甲苯磺酰赖氨酸氯甲基酮(TLCK)、胃蛋白酶抑制剂或α1-抗胰蛋白酶的抑制。控制增加蛋白酶产生的因子可能为关节炎提供一种新的治疗方法。